News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
741,487 Results
Type
Article (52988)
Company Profile (502)
Press Release (687997)
Section
Business (216882)
Career Advice (2833)
Deals (37198)
Drug Delivery (106)
Drug Development (86495)
Employer Resources (180)
FDA (17018)
Job Trends (15873)
News (367874)
Policy (35450)
Tag
Academia (2894)
Alliances (52847)
Alzheimer's disease (1314)
Approvals (16918)
Artificial intelligence (137)
Bankruptcy (379)
Best Places to Work (12136)
Biotechnology (370)
Breast cancer (121)
Cancer (1039)
Cardiovascular disease (92)
Career advice (2373)
Cell therapy (232)
Clinical research (68222)
Collaboration (364)
Compensation (175)
COVID-19 (2743)
C-suite (94)
Data (966)
Diabetes (152)
Diagnostics (6472)
Drug pricing (95)
Earnings (87191)
Employer resources (157)
Events (117384)
Executive appointments (268)
FDA (17497)
Funding (319)
Gene therapy (174)
GLP-1 (658)
Government (4774)
Healthcare (20022)
Infectious disease (2826)
Inflammatory bowel disease (113)
Interviews (549)
IPO (16873)
Job creations (4090)
Job search strategy (1968)
Layoffs (464)
Legal (8667)
Lung cancer (173)
Manufacturing (175)
Medical device (13827)
Medtech (13832)
Mergers & acquisitions (20340)
Metabolic disorders (426)
Neuroscience (1585)
NextGen Class of 2024 (7220)
Non-profit (4882)
Northern California (1339)
Obesity (252)
Opinion (225)
Patents (103)
People (61192)
Phase I (21203)
Phase II (29941)
Phase III (22345)
Pipeline (325)
Postmarket research (2919)
Preclinical (9156)
Radiopharmaceuticals (252)
Rare diseases (209)
Real estate (6428)
Regulatory (23338)
Research institute (2570)
Resumes & cover letters (452)
Southern California (1198)
Startups (3914)
United States (12964)
Vaccines (612)
Weight loss (201)
Date
Today (233)
Last 7 days (1103)
Last 30 days (3450)
Last 365 days (37400)
2024 (32902)
2023 (41886)
2022 (53212)
2021 (57876)
2020 (56601)
2019 (49837)
2018 (37693)
2017 (34712)
2016 (34538)
2015 (40637)
2014 (34685)
2013 (29997)
2012 (32065)
2011 (32509)
2010 (30801)
Location
Africa (910)
Arizona (203)
Asia (41970)
Australia (7621)
California (3081)
Canada (1223)
China (231)
Colorado (133)
Connecticut (141)
Europe (93657)
Florida (422)
Georgia (107)
Illinois (360)
Indiana (196)
Kansas (101)
Maryland (577)
Massachusetts (2521)
Michigan (151)
Minnesota (271)
New Jersey (898)
New York (905)
North Carolina (765)
Northern California (1339)
Ohio (134)
Pennsylvania (793)
South America (1288)
Southern California (1198)
Texas (425)
Washington State (356)
741,487 Results for "cellectar biosciences formerly known as novelos therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Ankyra Therapeutics and Jenga Biosciences Announce Exclusive License Agreement for JEN-101
Ankyra Therapeutics and Jenga Biosciences are pleased to announce today an exclusive license agreement to develop and commercialize JEN-101 (formerly known as cANK-101).
March 26, 2024
·
4 min read
Deals
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
Harmony Biosciences, announced the acquisition of Epygenix Therapeutics, Inc., accelerating its growth strategy by adding a rare epilepsy franchise to its expanding late-stage pipeline of innovative CNS assets.
April 30, 2024
·
9 min read
Press Releases
StimCell Energetics Inc. (Formerly “Cell MedX Corp.”) Announces Major Corporate Updates and Rebranding
November 4, 2024
·
3 min read
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.
June 17, 2024
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
BioMidwest
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.
May 29, 2024
·
5 min read
Business
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
G1 Therapeutics, Inc., a commercial-stage oncology company, and Deimos Biosciences, a portfolio company of Jupiter Bioventures, announced a global licensing agreement for lerociclib for radioprotective uses.
May 22, 2024
·
5 min read
Drug Development
Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk
Ventus Therapeutics, Inc. today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01).
May 3, 2024
·
6 min read
Deals
Pulse Biosciences, Inc. Announces Commencement of Rights Offering - June 4, 2024
Pulse Biosciences, Inc. today announced that it has commenced its previously announced rights offering of up to $60,000,000 of units (the “Units,” and each, a “Unit”) at the Initial Price (as defined below).
June 4, 2024
·
7 min read
Press Releases
PURE Bioscience Announces Distribution Agreement with Madison Chemical Co., Inc.
October 23, 2024
·
6 min read
1 of 74,149
Next